[2]
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group. Lancet (London, England). 1999 Jun 12;
[PubMed PMID: 10376616]
Level 1 (high-level) evidence
[4]
Sproat M,Pozniak AL,Peeters M,Winters B,Hoetelmans R,Graham NM,Gazzard BG, The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antiviral therapy. 2005;
[PubMed PMID: 15865231]
[5]
Perry CM,Balfour JA, Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 1996 Dec;
[PubMed PMID: 8957161]
[6]
Damle BD,Kaul S,Behr D,Knupp C, Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. Journal of clinical pharmacology. 2002 Jul;
[PubMed PMID: 12092746]
[7]
Seremeta KP,Tur MI,Pérez SM,Höcht C,Taira C,López Hernández OD,Sosnik A, Spray-dried didanosine-loaded polymeric particles for enhanced oral bioavailability. Colloids and surfaces. B, Biointerfaces. 2014 Nov 1;
[PubMed PMID: 25444665]
[8]
Schooley RT,Ramirez-Ronda C,Lange JM,Cooper DA,Lavelle J,Lefkowitz L,Moore M,Larder BA,St Clair M,Mulder JW,McKinnis R,Pennington KN,Harrigan PR,Kinghorn I,Steel H,Rooney JF, Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. The Journal of infectious diseases. 1996 Jun;
[PubMed PMID: 8648207]
[9]
Saravolatz LD,Winslow DL,Collins G,Hodges JS,Pettinelli C,Stein DS,Markowitz N,Reves R,Loveless MO,Crane L,Thompson M,Abrams D, Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. The New England journal of medicine. 1996 Oct 10;
[PubMed PMID: 8813040]
[10]
D'Aquila RT,Hughes MD,Johnson VA,Fischl MA,Sommadossi JP,Liou SH,Timpone J,Myers M,Basgoz N,Niu M,Hirsch MS, Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Annals of internal medicine. 1996 Jun 15;
[PubMed PMID: 8633815]
Level 1 (high-level) evidence
[11]
Foli A,Lori F,Maserati R,Tinelli C,Minoli L,Lisziewicz J, Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antiviral therapy. 1997 Jan;
[PubMed PMID: 11322264]
[12]
Butt AA, Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. The AIDS reader. 2003 Jul;
[PubMed PMID: 12889452]
[13]
Vogel M,Rockstroh JK, Hepatotoxicity and liver disease in the context of HIV therapy. Current opinion in HIV and AIDS. 2007 Jul;
[PubMed PMID: 19372904]
Level 3 (low-level) evidence
[14]
Ray AS,Olson L,Fridland A, Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrobial agents and chemotherapy. 2004 Apr;
[PubMed PMID: 15047506]
[15]
Hleyhel M,Goujon S,Delteil C,Vasiljevic A,Luzi S,Stephan JL,Reliquet V,Jannier S,Tubiana R,Dollfus C,Faye A,Mandelbrot L,Clavel J,Warszawski J,Blanche S, Risk of cancer in children exposed to didanosine in utero. AIDS (London, England). 2016 May 15;
[PubMed PMID: 26854809]
[16]
Blanchard JN,Wohlfeiler M,Canas A,King K,Lonergan JT, Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Sep 1;
[PubMed PMID: 12942419]
[17]
Tradati FC,Gringeri A,Santagostino E,Cultraro D,Simoni L,De Fazio C,Mezzi G,Cappelletti M,Malesci A,Mannucci PM, Prevalence of pancreatic disorders in HIV-infected hemophiliacs: diagnostic methods and their clinical significance. Biomedicine
[PubMed PMID: 7919111]
[18]
Gameiro J,Agapito Fonseca J,Jorge S,Lopes JA, Acute kidney injury in HIV-infected patients: a critical review. HIV medicine. 2019 Feb;
[PubMed PMID: 30411475]
[19]
Murphy MD,O'Hearn M,Chou S, Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Apr 15;
[PubMed PMID: 12684925]
[20]
Yombi JC,Jones R,Pozniak A,Hougardy JM,Post FA, Monitoring of kidney function in HIV-positive patients. HIV medicine. 2015 Sep;
[PubMed PMID: 25944246]
[21]
García-Benayas T,Rendón AL,Rodríguez-Novóa S,Barrios A,Maida I,Blanco F,Barreiro P,Rivas P,González-Lahoz J,Soriano V, Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS research and human retroviruses. 2006 Apr;
[PubMed PMID: 16623636]
[22]
Kakuda TN, Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical therapeutics. 2000 Jun;
[PubMed PMID: 10929917]
[23]
Whitcup SM,Butler KM,Caruso R,de Smet MD,Rubin B,Husson RN,Lopez JS,Belfort R Jr,Pizzo PA,Nussenblatt RB, Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. American journal of ophthalmology. 1992 Jan 15;
[PubMed PMID: 1728133]
[24]
Kuznik A,Iliyasu G,Habib AG,Musa BM,Kambugu A,Lamorde M, Initiation of antiretroviral therapy based on the 2015 WHO guidelines. AIDS (London, England). 2016 Nov 28;
[PubMed PMID: 27662547]